Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating BI-1206, a monoclonal antibody targeting CD32b, in combination with rituximab with or without acalabrutinib in adults with indolent B-cell Non-Hodgkin Lymphoma NHL that has relapsed or is resistant to rituximab. This Phase 12a, multicenter, open-label trial includes patients with follicular lymphoma except grade 3B, marginal zone lymphoma, and mantle cell lymphoma. The study involves dose escalation, signal seeking, and dose optimization phases to find the recommended BI-1206 dose. The study has two main parts Phase 1 involves dose escalation cohorts testing intravenous IV and subcutaneous SC BI-1206 combined with rituximab to determine safe doses. Phase 2a includes dose expansion of the selected IV dose with rituximab, signal seeking cohorts testing BI-1206 with rituximab and acalabrutinib both IV and SC, and a randomized dose optimization phase to select the best BI-1206 dose in combination with these drugs. Participants receive BI-1206 by injection or infusion, rituximab by infusion, and acalabrutinib orally. During the study, participants undergo safety monitoring, including tracking adverse events and determining dose-limiting toxicities over a 28-day induction period. Researchers assess pharmacokinetics, immune responses, B-cell depletion, and overall treatment response for up to one year. Participants are evaluated regularly with biopsies, blood tests, and clinical assessments to monitor disease status and treatment effects. The total duration depends on the study phase and dosing schedule, with ongoing safety and efficacy evaluations planned through 2027.
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
Actively Recruiting
Researchers are evaluating the effect of prasugrel plus low-dose aspirin compared to high-dose aspirin alone and low-dose aspirin alone in patients with stable coronary artery disease chronic coronary syndrome who have undergone coronary artery bypass grafting CABG. This phase 3, multicenter, randomized trial aims to assess graft failure and other health outcomes related to these antiplatelet therapies over a 12-month period. Participants will be randomly assigned to one of three groups prasugrel 10 mg plus low-dose aspirin 75 mg daily, high-dose aspirin 300 mg daily, or low-dose aspirin 75 mg daily. The treatment period lasts for three months, after which all participants will continue low-dose aspirin alone. The trial compares these regimens to determine their effects on graft failure and other cardiovascular events. During the study, participants will be monitored for graft failure incidence at 12 months and other outcomes such as ischemic and bleeding events, as well as quality of life over 12 and 60 months. Assessments include clinical follow-ups and evaluations to track adherence and safety. The total study duration covers up to five years to observe long-term effects after CABG surgery.
Actively Recruiting
Researchers are evaluating the effects of intravenous ferric carboxymaltose FCM compared with a placebo on death risk, heart failure events, NT-proBNP levels, and quality of life in patients who recently had an acute myocardial infarction AMI and have iron deficiency. This phase 4, multicenter, randomized, double-blind, placebo-controlled clinical trial aims to assess these outcomes over a follow-up period ranging from 8 to 36 months. Participants are randomly assigned to receive either an intravenous 15-minute infusion of 1000 mg FCM diluted in saline or a placebo infusion of saline alone. The first dose is given on the day of randomization, with follow-up visits at 4, 8, 12, 18, 24, and 30 months to reassess participants and possibly repeat treatment if safety criteria are met. During the study, participants undergo evaluations including monitoring of death rates, heart failure events such as unplanned hospitalizations or emergency visits, changes in NT-proBNP concentration, and quality of life measured by the EQ-5D questionnaire. Safety and treatment effects are tracked throughout the follow-up period, which can last up to 36 months from the start of participation.
Actively Recruiting
Researchers are evaluating the effect and safety of orforglipron taken once daily in adults with Fontaine Stage II peripheral arterial disease PAD, a condition that causes symptoms like leg pain due to poor blood flow. The study is a phase 3 randomized, double-blind, placebo-controlled trial aiming to better understand how this treatment impacts walking ability and quality of life in this population. Participation is expected to last about 58 weeks. Participants are randomly assigned to receive either orforglipron or a placebo, both taken orally once daily. The study compares these two groups to assess changes in walking distances and other health measures over the course of the trial. This design helps evaluate the medications effect compared to no active treatment. During the study, participants undergo assessments including measuring maximum and pain-free walking distances, vascular quality of life via questionnaire, the six-minute walk test, blood markers like high-sensitivity C-reactive protein, and systolic blood pressure. These measurements occur at the start and after 52 weeks of treatment. Safety and effectiveness are monitored throughout, with overall participation lasting nearly a year.
Actively Recruiting
Researchers are studying the long-term safety and tolerability of the drug NBI-1065845 when used alongside other treatments for adults with Major Depressive Disorder MDD. This Phase 3 trial focuses on participants who have moderate to severe recurrent MDD or persistent depressive disorder, particularly those who have not responded well to oral antidepressants in their current depressive episode. Participants will take NBI-1065845 tablets orally once a day as an additional treatment. The study is open-label and single group, meaning all participants receive the same treatment. The trial will observe participants over the course of one year while they take the medication. During the study, participants will undergo assessments to monitor any treatment-emergent adverse events from the start through week 52. Researchers will evaluate how well participants tolerate the medication and ensure their safety throughout the treatment period. The total participation duration corresponds to the one-year treatment and monitoring phase.
Actively Recruiting
Researchers are evaluating the performance of the Panuri test in detecting pancreatic ductal adenocarcinoma PDAC, the most common type of pancreatic cancer. This observational study focuses on adult patients who show symptoms suggesting pancreatic cancer or who are scheduled for procedures involving pancreatic cancer assessment. Panuri is a laboratory test designed to detect enzyme activity in urine samples related to PDAC, intended to support doctors in deciding if further imaging tests are needed. Participants will provide urine samples for the Panuri test during the study. The study includes two groups one with patients showing symptoms of pancreatic cancer and another with patients scheduled for pancreatic tissue assessment due to cancer suspicion. The test results will be kept blinded from both participants and physicians. Diagnosis confirmation will be done through review of electronic health records. Participants will be monitored from enrollment up to six months to assess how well the Panuri test detects PDAC. Data such as urine samples and medical records will be collected, but no treatment or intervention will be given as part of the study. The study aims to provide important information to help improve the diagnosis process for pancreatic cancer.
Actively Recruiting
Researchers are evaluating pembrolizumab combined with carboplatin and taxane chemotherapy followed by pembrolizumab with or without maintenance sacituzumab tirumotecan sac-TMT as a first-line treatment for metastatic squamous non-small cell lung cancer NSCLC. This phase 3 study aims to determine if adding maintenance sac-TMT improves overall survival compared to pembrolizumab alone. Participants first undergo an induction phase consisting of four cycles of pembrolizumab every three weeks, carboplatin every three weeks, and either paclitaxel every three weeks or nab-paclitaxel weekly. After induction, participants are randomly assigned to receive either pembrolizumab maintenance alone or pembrolizumab combined with sac-TMT maintenance. The maintenance phase involves pembrolizumab every six weeks for up to 96 weeks and sac-TMT infusions every two weeks until discontinuation criteria are met. Throughout the study, participants will have tumor assessments, scans, and evaluations to monitor disease status, side effects, and quality of life. Researchers will measure overall survival up to approximately 50 months and progression-free survival up to 79 months, along with patient-reported symptoms such as dyspnea, cough, and chest pain. Safety monitoring includes tracking adverse events and treatment discontinuations. The total participation may last several years as long-term outcomes are assessed.
Actively Recruiting
Researchers are evaluating how well seltorexant works and its safety when added to antidepressant treatment in adults and elderly participants with major depressive disorder who also experience insomnia symptoms. The study focuses on participants who have not adequately responded to treatment with selective serotonin reuptake inhibitors SSRIs or serotonin-norepinephrine reuptake inhibitors SNRIs. It aims to compare seltorexant with placebo as an additional therapy to improve depressive symptoms in this group. Participants will take seltorexant or a matching placebo orally once daily for 6 weeks during the double-blind phase of Part 1, while continuing their current SSRI or SNRI antidepressant. Those who complete Part 1 and meet criteria can enter Part 2, which includes open-label induction and stabilization phases where all receive seltorexant alongside their antidepressant. Participants who achieve a stable response then enter a double-blind maintenance phase in Part 2, receiving either seltorexant or placebo daily along with their antidepressant. During the study, participants will undergo assessments including depression rating scales like the Montgomery-Asberg Depression Rating Scale MADRS and patient-reported sleep disturbance measures. Researchers will monitor changes in depressive symptoms and sleep over time, track time to relapse during the maintenance phase, and evaluate safety. The total study duration may extend up to nearly three years for some participants, with follow-up after each treatment phase.
1-10 of 12
1